A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 129







List of co-cited articles
1037 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Loss of ZNF587B and SULF1 contributed to cisplatin resistance in ovarian cancer cell lines based on Genome-scale CRISPR/Cas9 screening.
Qianying Ouyang, Yujie Liu, Jieqiong Tan, Jie Li, Dawei Yang, Feiyue Zeng, Weihua Huang, Yi Kong, Zhaoqian Liu, Honghao Zhou,[...]. Am J Cancer Res 2019
13
7

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
M Raymond V Finlay, Mark Anderton, Susan Ashton, Peter Ballard, Paul A Bethel, Matthew R Box, Robert H Bradbury, Simon J Brown, Sam Butterworth, Andrew Campbell,[...]. J Med Chem 2014
282
1

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma.
Shiyong Li, Yoon-La Choi, Zhuolin Gong, Xiao Liu, Maruja Lira, Zhengyan Kan, Ensel Oh, Jian Wang, Jason C Ting, Xiangsheng Ye,[...]. J Thorac Oncol 2016
49
2

PIK3CA mutations and copy number gains in human lung cancers.
Hiromasa Yamamoto, Hisayuki Shigematsu, Masaharu Nomura, William W Lockwood, Mitsuo Sato, Naoki Okumura, Junichi Soh, Makoto Suzuki, Ignacio I Wistuba, Kwun M Fong,[...]. Cancer Res 2008
309
1

Lazertinib: First Approval.
Sohita Dhillon. Drugs 2021
1
100



Risk factors of Lung Cancer in nonsmoker.
Nahid Akhtar, Jeena Gupta Bansal. Curr Probl Cancer 2017
44
2

Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
Yuankai Shi, Shucai Zhang, Xingsheng Hu, Jifeng Feng, Zhiyong Ma, Jianying Zhou, Nong Yang, Lin Wu, Wangjun Liao, Dafang Zhong,[...]. J Thorac Oncol 2020
19
5

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Jody C Chuang, Henning Stehr, Ying Liang, Millie Das, Jane Huang, Maximilian Diehn, Heather A Wakelee, Joel W Neal. J Thorac Oncol 2017
54
1

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
Caicun Zhou, Suresh S Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J Riely, Tarek Mekhail, Danny Nguyen, Maria R Garcia Campelo, Enriqueta Felip,[...]. JAMA Oncol 2021
4
25

Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
Shanhe Wan, Ruohong Yan, Ying Jiang, Zhonghuang Li, Jiajie Zhang, Xiaoyun Wu. J Biomol Struct Dyn 2019
8
12

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
M Hidalgo, L L Siu, J Nemunaitis, J Rizzo, L A Hammond, C Takimoto, S G Eckhardt, A Tolcher, C D Britten, L Denis,[...]. J Clin Oncol 2001
827
1


Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Alison Reid, Laura Vidal, Heather Shaw, Johann de Bono. Eur J Cancer 2007
120
1

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.
Zhaolin Chen, Tianlu Shi, Lei Zhang, Pengli Zhu, Mingying Deng, Cheng Huang, Tingting Hu, Ling Jiang, Jun Li. Cancer Lett 2016
376
1

Osimertinib: First Global Approval.
Sarah L Greig. Drugs 2016
129
1

Personalizing therapy in advanced non-small cell lung cancer.
Liza C Villaruz, Timothy F Burns, Vasilis S Ramfidis, Mark A Socinski. Semin Respir Crit Care Med 2013
9
11

Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
Sung Keun Jung, Mee-Hyun Lee, Do Young Lim, Sung Young Lee, Chul-Ho Jeong, Jong Eun Kim, Tae Gyu Lim, Hanyong Chen, Ann M Bode, Hyong Joo Lee,[...]. Mol Carcinog 2015
30
3

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer.
Jiyun Lee, Joon Ho Shim, Woong-Yang Park, Hee Kyung Kim, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. Cancer Res Treat 2019
11
9

TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target.
Jiao-Jiao Yu, Dan-Dan Zhou, Xiao-Xiao Yang, Bing Cui, Feng-Wei Tan, Junjian Wang, Ke Li, Shuang Shang, Cheng Zhang, Xiao-Xi Lv,[...]. Nat Commun 2020
14
7

Targeting the EGFR signaling pathway in cancer therapy.
Parthasarathy Seshacharyulu, Moorthy P Ponnusamy, Dhanya Haridas, Maneesh Jain, Apar K Ganti, Surinder K Batra. Expert Opin Ther Targets 2012
428
1

The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer.
Yanming Deng, Weineng Feng, Jing Wu, Zecheng Chen, Yicong Tang, Hua Zhang, Jianmiao Liang, Haibing Xian, Shunda Zhang. Mol Clin Oncol 2014
73
1

Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
Martin H Cohen, John R Johnson, Somesh Chattopadhyay, Shenghui Tang, Robert Justice, Rajeshwari Sridhara, Richard Pazdur. Oncologist 2010
45
2

A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics.
Léonie Ferrer, Matteo Giaj Levra, Marie Brevet, Martine Antoine, Julien Mazieres, Giulio Rossi, Rita Chiari, Virginie Westeel, Michel Poudenx, Jacques Letreut,[...]. J Thorac Oncol 2019
31
3



Dacomitinib: First Global Approval.
Matt Shirley. Drugs 2018
26
3

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Shunli Peng, Rong Wang, Xiaojuan Zhang, Yueyun Ma, Longhui Zhong, Ke Li, Akihiro Nishiyama, Sachiko Arai, Seiji Yano, Wei Wang. Mol Cancer 2019
54
1

Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.
Giuseppe Altavilla, Carmela Arrigo, Maria Carmela Santarpia, Giuseppe Galletti, Giovanni Picone, Grazia Marabello, Chiara Tomasello, Vincenzo V Pitini. J Neurooncol 2008
20
5

Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
Heather Burnett, Helena Emich, Chris Carroll, Naomi Stapleton, Parthiv Mahadevia, Tracy Li. PLoS One 2021
7
14

Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Shi-Yu Jiang, Jing Zhao, Meng-Zhao Wang, Zhen Huo, Jing Zhang, Wei Zhong, Yan Xu. Medicine (Baltimore) 2016
36
2

[Impact of molecular targeting therapy on tumor immunity].
Masahisa Jinushi, Hirotoshi Akita. Nihon Rinsho 2015
1
100

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Yuxin Mu, Xuezhi Hao, Puyuan Xing, Xingsheng Hu, Yan Wang, Teng Li, Jinyao Zhang, Ziyi Xu, Junling Li. J Cancer Res Clin Oncol 2020
9
11

Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
Zhanhong Xie, Yingying Gu, Xinqing Lin, Ming Ouyang, Yinyin Qin, Jiexia Zhang, Junjun Liu, Suiyi Mai, Chengzhi Zhou. Cancer Biol Ther 2019
4
25

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Suresh S Ramalingam, Pasi A Jänne, Tony Mok, Kenneth O'Byrne, Michael J Boyer, Joachim Von Pawel, Adam Pluzanski, Mikhail Shtivelband, Lara Iglesias Docampo, Jaafar Bennouna,[...]. Lancet Oncol 2014
96
1

Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma.
Yingwen Li, Jingjing Wei, Yaohua Wei, Liang Cheng, Beibei Guo, Fenghua Meng, Feng Li, Zhiyuan Zhong. Biomacromolecules 2020
7
14


Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Lorenza Landi, Marcello Tiseo, Rita Chiari, Serena Ricciardi, Elisa Rossi, Domenico Galetta, Silvia Novello, Michele Milella, Armida D'Incecco, Gabriele Minuti,[...]. Clin Lung Cancer 2014
26
3

Afatinib: first global approval.
Rosselle T Dungo, Gillian M Keating. Drugs 2013
138
1

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients.
Si-Yang Liu, Hao Sun, Jia-Ying Zhou, Guang-Ling Jie, Zhi Xie, Yang Shao, Xian Zhang, Jun-Yi Ye, Chun-Xiang Chen, Xu-Chao Zhang,[...]. Biomark Res 2020
12
8


Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
Lai Wei, Derek Lee, Cheuk-Ting Law, Misty Shuo Zhang, Jialing Shen, Don Wai-Ching Chin, Allen Zhang, Felice Ho-Ching Tsang, Ceci Lok-Sze Wong, Irene Oi-Lin Ng,[...]. Nat Commun 2019
70
1

Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation.
Jessie Peh, Matthew W Boudreau, Hannah M Smith, Paul J Hergenrother. Cell Chem Biol 2018
11
9

Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
Yun-Ju Chen, Wei-Chien Huang, Ya-Ling Wei, Sheng-Chieh Hsu, Ping Yuan, Heather Y Lin, Ignacio I Wistuba, J Jack Lee, Chia-Jui Yen, Wu-Chou Su,[...]. PLoS One 2011
66
1

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Yiting Li, Hongjing Zang, Guoqing Qian, Taofeek K Owonikoko, Suresh R Ramalingam, Shi-Yong Sun. Cancer 2020
19
5

Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and superb treatment of orthotopic glioblastoma.
Qianyi Fan, Yuanyuan Liu, Guanhong Cui, Zhiyuan Zhong, Chao Deng. J Control Release 2021
6
16

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Shizhen Emily Wang, Archana Narasanna, Marianela Perez-Torres, Bin Xiang, Frederick Y Wu, Seungchan Yang, Graham Carpenter, Adi F Gazdar, Senthil K Muthuswamy, Carlos L Arteaga. Cancer Cell 2006
335
1

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
Paul E Hughes, Karen Rex, Sean Caenepeel, Yajing Yang, Yihong Zhang, Martin A Broome, Hue T Kha, Teresa L Burgess, Benny Amore, Paula J Kaplan-Lefko,[...]. Mol Cancer Ther 2016
36
2

Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD).
Tongji Xie, Yan Li, Jianming Ying, Weijing Cai, Junling Li, Kye Young Lee, Biagio Ricciuti, Jose Pacheco, Puyuan Xing. Transl Lung Cancer Res 2020
2
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.